2014 United States ASCO meeting prostate cancer highlights

Navigation:Home > Radiotherapy > Tumour > 2014 United States ASCO meeting prostate cancer highlights

[2014ASCO GU] prostate cancer highlights research summary2014-02-11 medical Naomaitong2014Genitourinary Cancers Symposium (2014ASCO GU; geni

Content

[2014ASCO GU] prostate cancer highlights research summary

2014-02-11 medical Naomaitong

2014Genitourinary Cancers Symposium (2014ASCO GU; genitourinary cancers Symposium) in January 2014 30-2 month 2 days held in San Francisco, attended the meeting of the Chris Tully MD as the research highlights we summarize the report on prostate cancer field, specific as follows:

Abstract number

Title

The key information

Abstract 4

High risk prostate cancer patients without metastasis were treated with hormone therapy alone or in combination with radiotherapy for 10 - and 15 year cancer related survival (SPCG VII)

The Bureau found long-term follow-up or histology for advanced treatment of invasive prostate cancer patients will separate application of androgen deprivation therapy or combined with radiotherapy and combined therapy can improve prostate cancer survival and overall survival. These results provide evidence for the efficacy of radiation therapy and lifetime androgen deprivation therapy.

Abstract 8

Screening for BRCA1 and BRCA2 mutations in prostate cancer patients to identify clinically important diseases: initial screening results for IMPACT studies.

When PSA was higher than the threshold of 3 ng/ml in patients with tissue biopsies, it appears that BRCA1/2 germline mutations in men are higher than those in the control group. The results suggest that early detection of prostate biopsy should be performed in patients at high risk of mutation, and the threshold value of PSA should be reduced.

Abstract 2

CA184-043 study on the overall survival results of the subgroup analysis: application of docetaxel in the treatment of metastatic prostate cancer after castration, comparing the efficacy of ipilimumab and placebo.

The contrast test of castration in patients with metastatic prostate cancer ipilimumab and placebo, the authors found a group of patients may be sensitive to immunotherapy (no organ disease, alkaline phosphatase, low hemoglobin > 11g/dL). This information may be helpful in the design of future trials and for patients who may be sensitive to this treatment.

Abstract 5

Results of phase III randomized trials: long term quality of life in patients with high risk prostate cancer.

This study suggests that the use of radiotherapy in the treatment of localized prostate cancer patients with high risk of short-term androgen deprivation therapy can improve the quality of life of patients, and does not shorten the survival period. The results provide further evidence for the use of short-term androgen deprivation therapy in patients with localized prostate cancer.

Abstract9

Phase ALSYMPCA III trial: 1.5 years of follow-up in patients with castration resistant prostate cancer and bone metastases treated with -223.

Long term follow-up of radium -223 does not appear to be associated with large safety problems or adverse reactions, and we can continue to use this approved drug.

Abstract 12

Denis monoclonal antibody or zoledronic acid treatment for castration resistant prostate cancer and bone metastasis in patients with the quality of life and the impact of cancer pain intervention.

Compared with zoledronic acid, Denis mAb seemingly can delay the onset of symptoms of malignant pain. This result may be selected Denis monoclonal antibody for the treatment of castration resistant prostate cancer and bone metastasis in patients with evidence.

Abstract 18

The effects on metastatic castration resistant prostate cancer patients were first applied to abiraterone enzalutamide activity.

The application of abiraterone after application of en 183 miscellaneous Lu amine treatment were retrospectively analyzed, more than 30% decline in PSA in 39% of the patients after treatment. This provides evidence for the continued use of these drugs in these patients.

Abstract 19

Analysis of factors associated with the development of biopsy

We pass to PSA< ng/ml; 10, < cT3, Gelisenshi score of 6 or less, 33% biopsy positive 518 men were actively monitoring found that 53% of the patients in the progress of the disease has not yet 5 years of follow-up. This summary indicates which patients can benefit from active monitoring to avoid aggressive treatment.

Abstract 130

The risk of pelvic magnetic resonance imaging on advanced prostate cancer classification function

The prostate MRI added to the PSA traditional risk classification + clinical tumor stage + biopsy Gelisenshi score, can help the patient to carry on the risk classification, so as to modify the treatment recommended.

Abstract 186

NaF PET/CT scanning precision can be found in castration resistant prostate cancer bone metastasis.

NaF PET/CT scan is more sensitive than detection of technetium -99 bone scan on bone lesions. This provides a theoretical basis for the detection of bone metastases in patients with prostate cancer.

Compiled from: Key Presentations ASCO 2014 Genitourinary Symposium: Cancer.PracticeUpdateFebruary Prostate 06, 2014, Cancers,

 

www.Cure001.comwww.Cure999.com

Cerebral Vascular Disease,Acne,Heart Disease,Deaf,Headache,Std,Condyloma Acuminatum,Fibroid,Pneumonia,Brain Trauma,。 Rehabilitation Blog 

Rehabilitation Blog @ 2017